Progress in the management of metastatic bladder cancer (Q33968726)

30 July 2017

1 reference

title

Progress in the management of metastatic bladder cancer (English)

1 reference

30 July 2017

Parimoo D

1

1 reference

30 July 2017

Raghavan D

series ordinal

2

1 reference

30 July 2017

publication date

1 July 2000

1 reference

30 July 2017

1 reference

30 July 2017

volume

7

1 reference

30 July 2017

issue

4

1 reference

30 July 2017

page(s)

347-356

1 reference

A randomized trial of cisplatin versus cisplatin plus methotrexate in advanced cancer of the urothelial tract

30 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1177/107327480000700404

Biology and management of bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/107327480000700404

A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/107327480000700404

Cisplatin, methotrexate, and vinblastine (CMV): an effective chemotherapy regimen for metastatic transitional cell carcinoma of the urinary tract. A Northern California Oncology Group study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/107327480000700404

Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/107327480000700404

High incidence of brain metastases in patients treated with an M-VAC regimen for advanced bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/107327480000700404

Clonal analysis of a bladder cancer cell line: an experimental model of tumour heterogeneity

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/107327480000700404

P-glycoprotein expression in primary and metastatic transitional cell carcinoma of the bladder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/107327480000700404

Increased mdr1 gene transcript levels in high-grade carcinoma of the bladder determined by quantitative PCR-based assay

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/107327480000700404

Expression of multidrug resistance-associated protein (MRP), MDR1 and DNA topoisomerase II in human multidrug-resistant bladder cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/107327480000700404

Expression of epidermal growth factor receptor in bladder cancer as related to established prognostic factors, oncoprotein (c-erbB-2, p53) expression and long-term prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/107327480000700404

Randomized phase II evaluation of carboplatin and CHIP in advanced transitional cell carcinoma of the urothelium. The Eastern Cooperative Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/107327480000700404

Enhancement of methotrexate nephrotoxicity after cisplatin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/107327480000700404

Escalated dosages of methotrexate, vinblastine, doxorubicin, and cisplatin plus recombinant human granulocyte colony-stimulating factor in advanced urothelial carcinoma: an Eastern Cooperative Oncology Group trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/107327480000700404

Dose-intensification of MVAC with recombinant granulocyte colony-stimulating factor as initial therapy in advanced urothelial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/107327480000700404

Significant activity of paclitaxel in advanced transitional-cell carcinoma of the urothelium: a phase II trial of the Eastern Cooperative Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/107327480000700404

Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/107327480000700404

Eastern Cooperative Oncology Group phase II trial of ifosfamide in the treatment of previously treated advanced urothelial carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/107327480000700404

An Eastern Cooperative Oncology Group phase II trial of trimetrexate in the treatment of advanced urothelial carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/107327480000700404

Weekly gemcitabine in advanced bladder cancer: a preliminary report from a phase I study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/107327480000700404

A phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum. Italian Co-operative Group on Bladder Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/107327480000700404

Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/107327480000700404

Gemcitabine: a promising new agent in the treatment of advanced urothelial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/107327480000700404

Gemcitabine plus cisplatin, an active regimen in advanced urothelial cancer: a phase II trial of the National Cancer Institute of Canada Clinical Trials Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/107327480000700404

Oral piritrexim, an effective treatment for metastatic urothelial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/107327480000700404

Phase II trial of oral piritrexim in advanced, previously treated transitional cell cancer of bladder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/107327480000700404

Phase II trial of vinblastine, ifosfamide, and gallium combination chemotherapy in metastatic urothelial carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/107327480000700404

Phase II randomized trial of gallium nitrate plus fluorouracil versus methotrexate, vinblastine, doxorubicin, and cisplatin in patients with advanced transitional-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/107327480000700404

Paclitaxel plus carboplatin in advanced carcinoma of the urothelium: an active and tolerable outpatient regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/107327480000700404

Paclitaxel and carboplatin in patients with metastatic transitional cell cancer of the urinary tract

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/107327480000700404

10.1177/107327480000700404

21 January 2018

Identifiers

DOI

0 references

1 reference